BridgeBio Pharma BBIO Reportable Segment — Other income, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — other income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — other income, net?
- BridgeBio Pharma (BBIO) reported reportable segment — other income, net of $4.25M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — other income, net changed year-over-year?
- BridgeBio Pharma's reportable segment — other income, net decreased by 48.3% year-over-year, from $8.23M to $4.25M.
- What does reportable segment — other income, net mean?
- Net income or expenses from activities outside of the company's primary business operations.
- How do you interpret reportable segment — other income, net?
- Higher values contribute positively to net income, though consistency is often low due to the non-core nature of these items.
- How does reportable segment — other income, net compare across companies?
- Common across all industries; investors look for stability or recurring trends in this line item.